GlassScriptPhysician profile
Keziya Mathew
NPI 1285205542
$830.26
in general payments reported to CMS, 2019-2025
15 companies · $29.19 in 2025
The $29.19 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $40.78 · 2022: $225 · 2023: $336 · 2024: $199 · 2025: $29.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $564.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $190.03 | 2021-2024 | Opdivo, Camzyos |
| Astrazeneca Pharmaceuticals LP | $177.99 | 2022-2024 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $70.72 | 2022-2024 | |
| Karyopharm Therapeutics INC. | $50.35 | 2022-2024 | Xpovio |
| Takeda Pharmaceuticals U.S.A., INC. | $48.03 | 2023-2024 | Entyvio |
| Alexion Pharmaceuticals, INC. | $46.40 | 2022-2023 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.43 | 2021-2022 | |
| Alcresta Therapeutics, INC. | $35.45 | 2023 | Relizorb |
| Argenx US, INC. | $30.55 | 2024 | Vyvgart Hytrulo |
| Novartis Pharmaceuticals Corporation | $29.19 | 2025 | |
| Glaxosmithkline, LLC. | $29.03 | 2023 | Trelegy Ellipta |
| Abbvie INC. | $22.02 | 2023 | |
| Grifols USA, LLC | $20.11 | 2024 | Gamunex-C |
| Bayer Healthcare Pharmaceuticals INC. | $20.00 | 2022 | |
| Incyte Corporation | $17.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keziya Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.